Accelerating precision medicine
Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “goal”, “intend”, “look forward to”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will”, “would” and similar expressions. The forward-looking statements contained herein represent the judgment of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.
Welcome

The Management Team

Werner Lanthaler
CEO*

Enno Spillner
CFO*

Craig Johnstone
COO*

Matthias Evers
CBO

Cord Dohrmann
CSO*
Agenda

Highlights

Financial performance H1 2022
Scientific and operational performance H1 2022
ESG, Outlook and Guidance 2022
**Significant new partnerships based on data-driven platforms**

**H1 2022 – Highlights & lowlights**

**Highlights**

- Major expansion and extension of targeted protein degradation alliance with BMS
- Several new integrated drug discovery, INDiGO, CMC, sample management agreements
- New collaborations with Almirall (dermatology), Boehringer Ingelheim (iPSC; Ophthalmology), Eli Lilly (E.MPD), Janssen (TargetAlloMod) and Sernova (iPSC; Diabetes)
- Strong demand and high capacity utilisation yields excellent gross margin in base business
- Just-Evotec Biologics still in its build-up phase; Number and value of new partnerships more than doubled versus H1 2021
- Co-owned pipeline projects progressing well
- Addition of cGMP cell therapy manufacturing through acquisition of Rigenerand, now Evotec (Modena)
- Expansion of EVOequity portfolio with new equity stakes in promising companies like e.g. Sernova

**Lowlights**

- Delays in pipeline milestones and of revenue recognition from scaling continuous biologics manufacturing
- Termination of development of P2X3 antagonist eliapixant by Bayer
- Strong headwinds from rising energy and material costs and overall inflation
Undisrupted demand from all industry sectors

- **Group revenues** up 24%  
  (€ 336.9 m vs. H1 2021: € 271.3 m)  
  - Like-for-like growth of Group revenues  
    (adj. for fx effects) up 19%  
  - Growth of base business (excl. milestones, upfront payments, licenses) up 26%  
- **Adjusted Group EBITDA**\(^3\) of € 33.6 m down 7%  
  (H1 2021: 36.2 m) balancing:  
  - Higher margin business and positive fx-effects  
  - Less milestones, upfront and license revenues, capacity expansion, ramp up of J.POD® Redmond (US), M&A related costs, energy and material costs as well as higher expenses for unpartnered R&D  

Guidance refined

- **Very good top-line growth expected**  
  - Total Group revenues **€ 715-735 m**  
    (April 2022: € 700 – 710 m); 2021: € 618 m  
    (€ 690-710 m at constant exchange rates\(^1\))  
- **Accelerated R&D investments for sustained growth**  
  - Unpartnered Group R&D expenses of **€ 70-80 m**\(^2\)  
    (2021: € 58 m)  
- **At least stable adj. EBITDA – investing in growth**  
  - Adjusted Group EBITDA\(^3\) **€ 105-120 m** (unchanged)  
    (2021: € 107.3 m)  
    (April 2022: € 95-110 m at constant exchange rates\(^1\))  
    (New: **€ 85-100 m at constant exchange rates\(^1\))

---

\(^1\) EUR/US$ 1.18; EUR/GBP 0.86  
\(^2\) Evotec focuses its guidance and upcoming reporting on the "unpartnered R&D" part. ID-related R&D expenses will be fully reimbursed by its partner Sanofi ("partnered R&D").  
\(^3\) Excluding M&A related costs and before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result.
Agenda

Highlights

Financial performance H1 2022

Scientific and operational performance H1 2022

ESG, Outlook and Guidance 2022
## Strong growth & investments into capacity, R&D, SG&A and M&A

Condensed income statement H1 2022 – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th></th>
<th>H1 2022</th>
<th>H1 2021</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>336.9</td>
<td>271.3</td>
<td>24%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>18.8%</td>
<td>20.8%</td>
<td>–</td>
</tr>
<tr>
<td>• R&amp;D expenses</td>
<td>(36.8)</td>
<td>(35.4)</td>
<td>4%</td>
</tr>
<tr>
<td>• SG&amp;A expenses</td>
<td>(67.4)</td>
<td>(46.4)</td>
<td>45%</td>
</tr>
<tr>
<td>• Impairment of intangible assets and goodwill</td>
<td>-</td>
<td>(0.7)</td>
<td>-</td>
</tr>
<tr>
<td>• Other op. income (expenses), net</td>
<td>37.7</td>
<td>34.5</td>
<td>9%</td>
</tr>
<tr>
<td>Operating result</td>
<td>(3.3)</td>
<td>8.3</td>
<td>nm</td>
</tr>
<tr>
<td>Adjusted Group EBITDA(^1)</td>
<td>33.6</td>
<td>36.2</td>
<td>(7)%</td>
</tr>
<tr>
<td>Net income</td>
<td>(101.2)</td>
<td>112.7</td>
<td>nm</td>
</tr>
</tbody>
</table>

- Revenue growth 24% (19%, adjusted for fx-effects)
- Increasing share of unpartnered R&D (+20%)
- SG&A up 45% due to upscaling at all sites, US-listing, consulting fees (M&A, digitalisation), energy costs, higher amortisations/deprecations
- Decline of adj. EBITDA due to change in revenue mix, and shift in cost structure
- Net income with impact from fair value adjustment of EVOequity investment Exscientia

\(^1\) Differences may occur due to rounding
\(^2\) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
High value alliances yield strong gross margin; Just – Evotec Biologics in build-up phase

Revenues & Gross margin overview – Evotec SE and subsidiaries

- Group base revenues up 26%, € 68.8 m to € 330.1 m.
- Group revenues of € 315.0 m - excluding Just – Evotec Biologics up 26%
- Just – Evotec Biologics revenues of € 21.9 m (H1 2021: €23.0 m); but growth of its base business up 23%
- Significant improvement of Group gross margin by 270 bps to 27.3% excluding Just – Evotec Biologics, despite lower contribution from milestones, upfronts and licenses and despite higher energy and material costs
## Strong performance across all business lines

Segment information H1 2022 – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th></th>
<th>EVT Execute</th>
<th>EVT Innovate</th>
<th>Inter-segment elimination</th>
<th>Evotec Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>351.0</td>
<td>78.0</td>
<td>(92.1)</td>
<td>336.9</td>
</tr>
<tr>
<td>Gross margin</td>
<td>17.4%</td>
<td>12.4%</td>
<td>–</td>
<td>18.8%</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td>(2.6)</td>
<td>(42.0)</td>
<td>7.8</td>
<td>(36.8)</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>(54.1)</td>
<td>(13.3)</td>
<td>–</td>
<td>(67.4)</td>
</tr>
<tr>
<td>Impairment of intangible assets and goodwill</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other op. income (expenses), net</td>
<td>15.6</td>
<td>22.2</td>
<td>–</td>
<td>37.7</td>
</tr>
<tr>
<td>Operating result</td>
<td>20.1</td>
<td>(23.4)</td>
<td>–</td>
<td>(3.3)</td>
</tr>
<tr>
<td>Adjusted EBITDA$^2)$</td>
<td>54.7</td>
<td>(21.1)</td>
<td>–</td>
<td>33.6</td>
</tr>
</tbody>
</table>

- Very strong growth versus H1 2021
- EVT Execute: 26% growth including inter-segment revenues (+41%); 21% growth of external revenues driven by strong base business; Growth of external revenues excluding Just – Evotec Biologics: +24%
- EVT Innovate: 36% growth in H1 2022 after 27% in Q1 2022 implies further improving demand for precision medicine platforms
- Adjusted Group EBITDA influenced by increased R&D investments, energy and material costs, M&A costs as part of higher SG&A costs

---

$^1)$ Differences may occur due to rounding
$^2)$ Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
## Sequential growth acceleration yields margin improvement

**Condensed income statement Q2 2022 – Evotec SE and subsidiaries**

<table>
<thead>
<tr>
<th></th>
<th>Q2 2022</th>
<th>Q2 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>172.2</td>
<td>138.2</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td>17.9%</td>
<td>18.5%</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>(18.7)</td>
<td>(17.0)</td>
</tr>
<tr>
<td><strong>SG&amp;A expenses</strong></td>
<td>(35.8)</td>
<td>(25.2)</td>
</tr>
<tr>
<td><strong>Impairment of intangible assets</strong></td>
<td>–</td>
<td>(0.7)</td>
</tr>
<tr>
<td><strong>Impairment of goodwill</strong></td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Other op. income (expenses), net</strong></td>
<td>19.9</td>
<td>18.8</td>
</tr>
<tr>
<td><strong>Operating result</strong></td>
<td>(3.8)</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Adjusted Group EBITDA</strong></td>
<td>14.8</td>
<td>15.1</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>(27.9)</td>
<td>60.0</td>
</tr>
</tbody>
</table>

- Base revenues accelerated in Q2 versus Q1 2022 across all business lines suggesting robust demand and limited impact from changing funding environment
- R&D investments accelerated – as planned
- SG&A reflects further dynamic growth, scaling and strategic projects
- Adj. EBITDA stable versus previous year level despite significantly higher energy costs and M&A
- **EVOequity**: Net Income impacted by non-cash fair value adjustment of Exscientia stake

---

1) Differences may occur due to rounding
2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
### Strong balance sheet supports accelerated growth

Balance sheet and liquidity – 31 Dec. 2021 vs. 30 June 2022\(^1\) – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th>Balance sheet total in € m</th>
<th>Equity Ratio in %</th>
<th>Liquidity position in € m</th>
<th>Net Debt ratio (excl. IFRS 16) x adjusted EBITDA(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,235.2</td>
<td>61.6</td>
<td>858.2</td>
<td>(5.5)</td>
</tr>
<tr>
<td>2,293.7</td>
<td>55.6</td>
<td>887.9</td>
<td>(6.4)</td>
</tr>
</tbody>
</table>

- Total assets increased by ~3%
- With upfront payment received from BMS, net debt leverage ratio further expanded to -6.4 x adjusted EBITDA excl. IFRS 16
- Equity ratio reduction predominantly due to fair value adjustment of Exscientia share
- Strong operating cash in-flow, also due to BMS upfront, vs. liquidity outflow for further expansion, ramp up and M&A resulting in a net increase of liquidity

\(^1\) Differences may occur due to rounding

\(^2\) Versus 31 Dec 2021; incl. IFRS16 (5.8) (30 Jun 2022 vs (3.2) (31 Dec 2021)
Agenda

Highlights

Financial performance H1 2022

Scientific and operational performance H1 2022

ESG, Outlook and Guidance 2022
Platforms and technologies for more precision and efficiency

Evotec today – 16 Sites and more than 4,400 employees

USA
>500
- Branford
- Princeton
- Redmond, WA
- Seattle
- Watertown

Austria
~40
- Orth an der Donau

Italy
>850
- Verona (Campus Levi-Montalcini)
- Modena

Germany
>1,050
- Hamburg (HQ)
- Goettingen (Manfred Eigen Campus)
- Cologne
- Munich

UK
>950
- Abingdon (Dorothy Crowfoot Hodgkin Campus)
- Alderley Park

France
>950
- Lyon
- Toulouse (Campus Curie)
Developing precise medicines with panomics & tech convergence

Overview

Data-driven R&D Autobahn to Cures – combining all relevant parts for an integrated, end-to-end approach

R&D efficiency platforms

Precision medicine platforms

Right modality drug design

Just – Evotec Biologics

EVOpanHunter
EVOpanOmics
EVOgnostic
E.ipSC
E.MPD
ScreenSeq
ScreenPep
E.SAFETY
E.iBETA
EVOgenes
EVOcells
E.RNA
Antibodies & Bifunctionals
Antisense
Exosomes
Protein degradation
Small molecules

Developing precise medicines with panomics & tech convergence
New and extended alliances underline growth strategy

Highlights in H1 2022

- Several new and extended integrated drug discovery agreements
- Increased demand for CMC (Integrated Chemistry, Manufacturing and Control) capabilities
- Continued strong performance of high-throughput DMPK / ADME-tox testing

- Medical Dermatology; Multi-target; AI / ML-driven EVOiR&D platform; Upfront & research payments; up to € 230 m per project; royalties
Continued strong partnerships with precision medicine platforms
Overview in H1 2022

**Data-driven R&D Autobahn to Cures**

<table>
<thead>
<tr>
<th>R&amp;D efficiency platforms</th>
<th>Precision medicine platforms</th>
<th>Right modality drug design</th>
<th>Just – Evotec Biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Boehringer Ingelheim</strong></td>
<td><strong>Ophtalmology; iPSC- and EVOpanOmics;</strong> Undisclosed upfront and milestone payments, layered royalties</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bristol Myers Squibb</strong></td>
<td><strong>Neurodegeneration; iPSC and expansion on target protein degradation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bristol Myers Squibb</strong></td>
<td><strong>Target protein degradation / molecular glues; EVOpanOmics &amp; EVOpanHunter; € 200 m upfront, up to € 5 bn deal value, tiered royalties</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lilly</strong></td>
<td><strong>Kidney diseases &amp; diabetes; E.MPD; EVOpanOmics; Undisclosed upfront payment; Five programmes with milestone payments of up to US$180 m per programme, tiered royalties</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>janssen</strong></td>
<td><strong>Protein homeostasis; TargetAlloMod; up to € 210 m milestone payment per project, tiered royalties</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Delivering health by expanding & improving cell therapy research

Overview H1 2022

- QRBeta 1.0 – First generation cell therapy for Insulin-dependent diabetes
- iPSC-based beta cells combined with Cell Pouch™

- Acquisition of Rigenerand Srl, Medolla, Italy, now operating as Evotec (Modena) Srl
- Evotec Cell Accelerator: cGMP manufacturing as basis for off-the-shelf cell therapies
Evotec Cell Accelerator takes cell therapy to the next level

**EVOcells** – World-class end-to-end infrastructure

- Cell therapies can deliver ‘functional cures’ to patients
- Evotec is a leader in producing iPSC derived cell types and organoids at highest quality and industrial scale
- Evotec (Modena) expands capacity with a dedicated cell therapy manufacturing site and skilled team of cell therapy experts
- Being able to produce large quantities of cGMP cell therapy material makes Evotec the ideal partner for integrated research & development of cell therapy approaches

### iPSC Platform
- iPSC-derived cell types
- Gene editing

### QC & upscaling
- Oncology expertise
- Pre-clinical development & CMC

### Clinical manufacturing
- Clinical Phase I / II / III
- Market supply
- Marketing and Sales

### Market supply

<table>
<thead>
<tr>
<th>iPSC-derived cell types</th>
<th>ArrayCGH, karyotyping, WGS</th>
<th>Single cell sequencing</th>
<th>3D expansion</th>
<th>Upscaling</th>
<th>Cell QC</th>
<th>GMP production</th>
</tr>
</thead>
</table>

---

1 Clinical trials, Marketing and Distribution managed by partners
# Building a iPSC-based cell therapy pipeline

## Internal off-the-shelf cell therapy programmes

<table>
<thead>
<tr>
<th>Field</th>
<th>Program / Project</th>
<th>Disease area</th>
<th>Exploratory</th>
<th>Pre-clinical research</th>
<th>Pre-clinical development</th>
<th>IND / Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-tumour cell therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iNK</td>
<td>IO&lt;sup&gt;1)&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iM</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>γδ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>αβ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Regenerative therapy</strong></td>
<td>S. E. IBETA Sernova Cell Pouch™</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iCM</td>
<td>Heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune-modulation</strong></td>
<td>iMSCs, iMSC exosomes</td>
<td>Various</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iNK, iTreg</td>
<td>Anti-fibrotic, auto-immune</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### iPSC-based cell types

- **iNK**: Natural killer cells
- **iT**: αβ and γδ T cells
- **iM**: Macrophages
- **iBeta**: Pancreatic islets
- **iCM**: Cardiomyocytes
- **iMSC**: Mesenchymal stromal cells

<sup>1</sup> Immuno-oncology
Shaping the value proposition to meet future demand

Just – Evotec Biologics development update

Data-driven R&D Autobahn to Cures

R&D efficiency platforms

Precision medicine platforms

Right modality drug design

Just – Evotec Biologics

J.POD® Toulouse (France) EU: construction work about to start

Number of partnerships and volume of sales order book already doubled in H1 2022 versus 2021; Latest Alpine Immune Sciences extension to design commercial manufacturing process

Just – Evotec Biologics is still in its build up and initial investment phase, but nevertheless on track to meet AP 2025 goals, despite delayed revenues in 2022
Continuous process outperforming fed batch 20x

Large scale production readiness is imminent

Fully end-to-end continuous process for late-stage products (> 25-day production)

Kg DS\(^1\) per Bioreactor

1\(^{st}\) DS = Drug Substance
## Programmes of partners with increasing breadth and depth

### Just – Evotec Biologics client programmes

<table>
<thead>
<tr>
<th>Disease area</th>
<th>No. of programmes</th>
<th>Discovery</th>
<th>J.MD Optimization</th>
<th>Pre-clinical development</th>
<th>Clinical manufacturing</th>
<th>Commercial Manufacturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other / undisclosed</td>
<td>ND(^1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Broad basis for sustained growth
- > 15 partners / 18 programmes
- Well balanced partner structure
  - Large / Mid-sized Pharma
  - Large / Small Biotech
  - Foundations
- Continued emphasis on optimal value mix of
  - Fee for service
  - **EVO**royalty
  - **EVO**equity
- Better access to affordable medicine for all
  >50% of programmes addressing targets set to reach UN SDG 3\(^2\)

\(^1\) Not Disclosed
\(^2\) United Nations Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages
Strong growth of biologics business

New programme wins and sales orderbook value

- Number of newly signed programmes in H1 2022 already exceeds number during FY 2021
- New contracts carry significantly higher value than in FY2021
- Progress of projects through development process (discovery, clinical, commercial) and new signings will result in acceleration of business pipeline growth
Selected pipeline events within next 12 – 24 months

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia in Oncology (EVT801)
- Phase Ib / II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I initiation with Bayer in Kidney diseases
- Phase I initiations with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Therapeutic Area / Indication</th>
<th>Partner</th>
<th>Discovery</th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVT201</td>
<td>Insomnia (GABA-A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Infectious Disease (Antibody)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAY2395840</td>
<td>Diabetic Neuropathic Pain (B1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT7001</td>
<td>Oncology (CDK7)</td>
<td>Carrick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XP-105</td>
<td>Oncology (mTORC1/2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT401</td>
<td>Immunology &amp; Inflammation (P2X7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAY2328065</td>
<td>Gynaecology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXS21546</td>
<td>Oncology (various programmes)</td>
<td>Exscientia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT894</td>
<td>Chikungunya (Antibody)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Neuroscience &amp; Pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Neuroscience &amp; Pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT801</td>
<td>Oncology (VEGFR3)</td>
<td>Kazia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT8683</td>
<td>Neurodegeneration (eIF2b activator)</td>
<td>Bristol Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPM203</td>
<td>Pemphigus Vulgaris (ND)</td>
<td>Topas Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT7001</td>
<td>Oncology (CDK7)</td>
<td>Carrick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT77001</td>
<td>Oncology (CDK7)</td>
<td>Carrick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APN411</td>
<td>Oncology – Immunotherapy</td>
<td>Sanofi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLPGxxxx</td>
<td>Fibrosis (not disclosed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAYyyyy</td>
<td>Nephrology (not disclosed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QR8001</td>
<td>Metabolic – Diabetes (not disclosed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT705</td>
<td>Covid-19 / HBV</td>
<td>Bristol Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Various programmes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVTxxxx</td>
<td>CNS, Metabolic, Pain, …</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Multiple programmes across nephrology, oncology, immunology among other therapeutic areas
**EVOequity accelerates co-owning strategy**

Operational VC model – diversified portfolio with multiple shots on goal

---

**At Equity Holding (≥20%) or Significant influence**

- Eternygen
- Topas Therapeutics
- facio therapies
- AUTOBAHN LABS
- BREAKPOINT Therapeutics
- celmatix
- DARK BLUE Therapeutics
- CUREXSYS
- panCELLa
- QUANTR Therapeutics
- NophThera

---

**Minority Shareholdings (<20%)**

- Carrick Therapeutics
- Exscientia
- FORGE Therapeutics
- TUBULUS
- LEON Therapeutics
- mission
- Cajal Neuroscience
- Immunitas
- BLACKSMITH
- ARGOBIO
- OXVAX
- IMIMedica
- Centauro
- Aramis Therapeutics
- Sernova

---

**BRIDGEs**

- LAB282
- LAB150
- AUTOBAHN LABS
- DANUBE LABS
- ARGOBIO Studio
- beLAB2122
- beLAB1407

---

[https://actionplan.evotec.com/evoequity](https://actionplan.evotec.com/evoequity)
Agenda

Highlights

Financial performance H1 2022

Scientific and operational performance H1 2022

ESG, Outlook and Guidance 2022
Keeping the promise

ESG & Sustainability – Measures taken in H1 2022

- Environment
  - Starting final phase of SBTi alignment project: Scope 3 emission assessment
  - Installation of first air source heat pump (Building B95 in Abingdon)

- Social
  - Expansion of investments in disease areas under UN SDG3
  - Launch of Aurobac Therapeutics, JV with Boehringer Ingelheim and bioMérieux; Targeting Antimicrobial Resistance (“AMR”) with next generation antimicrobials and diagnostics
  - Diversity Month and Pride Month; Joined Proud Science Alliance; Evotec @ London Pride

- Governance
  - Governance roadshow of Chairwoman of Supervisory Board
  - Formation of ESG Committee within the Supervisory Board
  - Implementation of Supplier Code of Conduct
## Guidance refinement – On track towards reaching AP 2025 goal

### Guidance 2022

<table>
<thead>
<tr>
<th></th>
<th>Guidance 2022</th>
<th>YE 2021</th>
<th>Implied growth at midpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group revenues (H1 2022)</strong></td>
<td>€ 715 – 735 m</td>
<td></td>
<td>&gt;15%</td>
</tr>
<tr>
<td>Group revenues (FY 2021 call)</td>
<td>€ 700 – 720 m</td>
<td>€ 618 m</td>
<td>~15%</td>
</tr>
<tr>
<td>(at constant fx-rates(^1))</td>
<td>(€ 690 – 710 m)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unpartnered R&amp;D(^2)</strong></td>
<td>€ 70 – 80 m</td>
<td>€ 58 m</td>
<td>~30%</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA(^3)</strong></td>
<td>€ 105 – 120 m</td>
<td></td>
<td>At least stable</td>
</tr>
<tr>
<td>(at constant fx-rates(^3); H1 2022)</td>
<td>(€ 85 – 100 m)</td>
<td>€ 107 m</td>
<td></td>
</tr>
<tr>
<td>(at constant fx-rates(^3); FY 2021 call)</td>
<td>(€ 95 – 110 m)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

\(^1\) EUR/US$ 1.18; EUR/GBP 0.86

\(^2\) No material FX effects as most R&D efforts are carried out in € area

\(^3\) Excluding M&A related costs and before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
Our mid-term aspirations are “… just the beginning”

2020-2025e Key Performance Indicator goals

<table>
<thead>
<tr>
<th>Category</th>
<th>Goal</th>
<th>Achieved Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues in € m</td>
<td>&gt;100%</td>
<td>500.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;1,000</td>
</tr>
<tr>
<td>Adjusted EBITDA¹ in € m</td>
<td>≥180%</td>
<td>106.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥300</td>
</tr>
<tr>
<td>Unpartnered R&amp;D in € m</td>
<td>&gt;100%</td>
<td>464</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;100</td>
</tr>
<tr>
<td>Co-owned projects²</td>
<td>&gt;100%</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;250</td>
</tr>
</tbody>
</table>

¹ Before significant royalties
² Incl. Equity participations
### Setting the pace to accelerate growth along Action Plan 2025

Next key events to watch

| R&D efficiency platforms | • Continued >15% growth of base business (**EVOiR&D**)  
<table>
<thead>
<tr>
<th></th>
<th>• Significant capacity and value chain expansion for all modalities and sites</th>
</tr>
</thead>
</table>
| Precision medicine platforms | • New partnerships, important milestones  
|                        | • Multiple clinical trial initiations and progression of co-owned pipeline; (**EVOroyalty**)  
|                         | • Spin-Offs and investments along AP 2025 (**EVOequity**) |
| Just – Evotec Biologics | • Start of production J.POD® Redmond, WA (US);  
|                         | • Groundbreaking for J.POD® Toulouse, France (EU);  
|                         | • Multiple new partnerships (**EVOaccess**) |
Looking forward to seeing you in person

Financial calendar 2022

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarterly Statement Q1 2022</td>
<td>11 May 2022</td>
</tr>
<tr>
<td>Virtual Annual General Meeting 2022</td>
<td>22 June 2022</td>
</tr>
<tr>
<td>Half-year 2022 Interim Report</td>
<td>11 August 2022</td>
</tr>
<tr>
<td>Capital Markets Day in Seattle / Redmond</td>
<td>02 November 2022</td>
</tr>
<tr>
<td>Quarterly Statement 9M 2022</td>
<td>09 November 2022</td>
</tr>
</tbody>
</table>
On site at Just – Evotec Biologics

In person and virtual

Capital Markets Day on 02 November 2022
QUESTIONS AND ANSWERS
Your contact:

Volker Braun  
Head of Global Investor Relations & ESG  
+49.0.40.560 81-775  
+49.0.40.560 81-333 Fax  
volker.braun@evotec.com